{"nctId":"NCT05265065","briefTitle":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","startDateStruct":{"date":"2022-05-27","type":"ACTUAL"},"conditions":["COVID-19"],"count":601,"armGroups":[{"label":"Standard Pfizer-BioNTech booster group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Tozinameran - Standard Dose"]},{"label":"Fractional Pfizer-BioNTech booster group","type":"EXPERIMENTAL","interventionNames":["Biological: Tozinameran - Fractional Dose"]}],"interventions":[{"name":"Tozinameran - Standard Dose","otherNames":["BNT162b2","Comirnaty","Pfizer Covid-19 vaccine"]},{"name":"Tozinameran - Fractional Dose","otherNames":["BNT162b2","Comirnaty","Pfizer Covid-19 vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Have completed two doses of Sinopharm, AstraZeneca or Sputnik vaccines with the recommended schedule 6 months prior to the date of enrolment\n2. Willing and able to give written informed consent\n3. Aged 18 years or above\n4. Willing to complete the follow-up requirements of the study\n\nExclusion Criteria:\n\n1. Received 3 doses of COVID-19 vaccine\n2. Received 2 doses of COVID-19 less than 6 months prior to the start of the trial\n3. Currently on immunosuppressive medication or anti-cancer chemotherapy\n4. HIV infection\n5. Congenital immune deficiency syndrome\n6. Has received immunoglobulin or other blood products in the 3 months prior to vaccination\n7. Study staff and their relatives\n8. Have a history of a severe allergic reaction to any COVID-19 vaccines or have a medical exception to receiving further COVID-19 vaccines","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Seroresponse","description":"Serum samples collected at 28-days post booster vaccination from all groups will be evaluated for SARS-CoV-2 specific IgG antibodies using IgG ELISA. The primary endpoint is the seroresponse rate at the Day-28 visit. The seroresponse rate at the individual level is defined as either a ≥4-fold rise in binding antibodies at the Day-28 visit compared to baseline (pre-vaccination) with a titre of \\<200 BAU/ml, a ≥2-fold rise among participants with a baseline (pre-vaccination) titre of \\>200 BAU/ml, or a ≥4-times the lower limit of detection if baseline levels are lower than the limit of detection.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"250","spread":null}]}]}]},{"type":"PRIMARY","title":"Solicited Grade 3 or 4 Local or Systemic Reaction","description":"Questionnaire to document solicited reactions is developed specifically for this study. Data will be reported as the proportion of participants who report grade 3 or 4 reactions by each intervention arm. Solicited reactions such as pain, tenderness, erythema/redness, induration, swelling, fever, nausea, vomiting, headache, fatigue/malaise, myalgia, arthralgia, diarrhea, enlarged lymph nodes will be collected from the participants 7 days post-vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroresponse by Priming Vaccine Strata","description":"Serum samples collected at 28-days post booster vaccination from all groups will be evaluated for SARS-CoV-2 specific IgG antibodies using IgG ELISA. The primary endpoint is the seroresponse rate at the Day-28 visit. The seroresponse rate at the individual level is defined as either a ≥4-fold rise in binding antibodies at the Day-28 visit compared to baseline (pre-vaccination) with a titre of \\<200 BAU/ml, a ≥2-fold rise among participants with a baseline (pre-vaccination) titre of \\>200 BAU/ml, or a ≥4-times the lower limit of detection if baseline levels are lower than the limit of detection.\n\nPriming strata (previously COVID vaccination): AstraZeneca (ChAdOx1-S, or Vaxzevria®); Sinopharm (BBIBP-CorV®); Sputnik V (Gam-COVID-Vac®)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"170","spread":null},{"groupId":"OG003","value":"169","spread":null},{"groupId":"OG004","value":"28","spread":null},{"groupId":"OG005","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"SARS-CoV-2 Specific IgG Antibodies at Day-28","description":"Serum samples collected at 28-days post booster vaccination from all groups will be evaluated for SARS-CoV-2 specific IgG antibodies using IgG ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4946","spread":null},{"groupId":"OG001","value":"4619","spread":null}]}]}]},{"type":"SECONDARY","title":"SARS-CoV-2 Specific IgG Antibodies at Day-28 by Priming Vaccine Strata","description":"Serum samples collected at 28-days post booster vaccination from all groups will be evaluated for SARS-CoV-2 specific IgG antibodies using IgG ELISA.\n\nPriming strata (previously COVID vaccination): AstraZeneca (ChAdOx1-S, or Vaxzevria®); Sinopharm (BBIBP-CorV®); Sputnik V (Gam-COVID-Vac®)","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4394","spread":null},{"groupId":"OG001","value":"4167","spread":null},{"groupId":"OG002","value":"5109","spread":null},{"groupId":"OG003","value":"4970","spread":null},{"groupId":"OG004","value":"5160","spread":null},{"groupId":"OG005","value":"3662","spread":null}]}]}]},{"type":"SECONDARY","title":"SARS-CoV-2 Specific IgG Antibodies at Baseline (Pre Booster), 28- Days, 6- and 12-months Post Booster Vaccination.","description":"Serum samples collected at baseline (pre booster), 28 days, 6- and 12-months post booster vaccination from all groups will be evaluated for SARS-CoV-2 specific IgG antibodies using IgG CMIA. Data will be reported as binding antibody units (BAU)/mL and presented as geometric mean concentration (GMC) and 95% confidence intervals (CI).","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"SARS-CoV-2 Specific Neutralising Antibodies at Baseline (Pre Booster), 28 Days-, 6- and 12-months Post Booster Vaccination Measured by Surrogate Virus Neutralization Test (sVNT).","description":"Serum samples collected at baseline (pre booster), 28 days-, 6- and 12-months post booster vaccination from all groups will be evaluated for SARS-CoV-2 specific neutralising antibodies using the GenScript® cPass surrogate virus neutralization test (sVNT) for both wild-type and Omicron variant. Neutralising antibody response will be reported as percentage (%) inhibition of receptor binding domain-angiotensin-converting enzyme 2 (RBD-ACE2) binding relative to a positive control.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"SARS-CoV-2 Specific Neutralising Antibodies at Baseline (Pre Booster), 28 Days-, 6- and 12-months Post Booster Vaccination Measured by SARS-CoV-2 Microneutralisation Assay","description":"A subset of samples (20%) from all four timepoints will be assessed using a SARS-CoV-2 microneutralisation assay to both the wild type (vaccine) strain and for two SARS-CoV-2 Variants of concern. Neutralizing antibody will be reported as endpoint titre.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Interferon Gamma (IFNγ) Concentrations in International Units (IU)/mL","description":"Applicable to the subset participants with additional blood collection. Interferon gamma (IFNγ) concentrations as a measurement of cellular immunity will be assessed on a subset of the participants from each group. QuantiFERON Human IFN-γ SARS-CoV-2 (Qiagen) will be used to stimulate IFN-γ production in peripheral blood mononuclear cells (PBMCs) and then IFN-γ production will be measured using ELISA (enzyme-linked immunosorbent assay). Data will be presented as GMC and 95% CI.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of IFNγ Producing Cells/Million PBMCs","description":"Applicable to the subset participants with additional blood collection. IFNγ producing cells as a measurement of cellular immunity will be assessed on a subset of the participants (40%) from each group. IFN-γ Enzyme-Linked ImmunoSpot (Elispot) assay will be performed on isolated peripheral blood mononuclear cells (PBMCs). Data will be reported as number of IFNγ producing cells/million and presented using means and 95% CI.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Frequency of Cytokine-expressing T Cells","description":"Frequency of cytokine-expressing T cells will be assessed on a subset of participants (40%) using flow cytometry (intracellular staining) on PBMCs samples. Data will be reported as frequency (%) of cytokine-expressing T cells presented as means and 95% CI.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Cellular Immunity: Multiplex Cytokine Assays - Reported as Cytokine Concentrations in pg/ml and Presented as GMC and 95% CI","description":"Cytokine concentrations following PBMCs stimulation will be assessed on a subset of participants (40%) using multiplex cytokine assays.Data will be reported as cytokine concentrations in pg/ml and presented as GMC and 95% CI.IFN-γ Elispot, intracellular cytokine assays (flow cytometry) and multiplex cytokine assays will be performed on isolated PBMCs.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence of Unsolicited Adverse Events (AE)","description":"All unsolicited AE will be collected for 28 days post booster vaccination. Data will be presented as proportion of participants who report unsolicited AE.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Medically Attended Adverse Events","description":"All participants with medically attended AE will be collected for 3 months post booster vaccination. Data will be presented as proportion of participants who report unsolicited AE.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence of Serious Adverse Events (SAE)","description":"SAE will be collected throughout the follow-up period of 12 months post booster vaccination. Data will be presented as a proportion of participants who report unsolicited SAE.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence of PCR Confirmed COVID-19 Infection","description":"Confirmed COVID-19 infections will be documented throughout the follow-up period, by clinical severity.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":65},"commonTop":["Headache","Hypertension","Acute respiratory tract infection","Upper respiratory tract infection","Acute upper respiratory tract infection"]}}}